Pharmaceutical Sector

AstraZeneca posts jump in 3Q earnings on H1N1 vaccine

The pharmaceutical company AstraZeneca reported an increase of 24 per cent in pre-tax profits to $3.4 billion for the third quarter, partly owing to strong sales of its swine flu vaccine.

AstraZeneca said its revenue for the three months ended September was up by more than 5 per cent, while margins jumped 44 per cent.

Cholesterol drug Crestor reported sales of $1.1 billion, representing an increase of 30 per cent.

Sales of Toprol-XL also jumped 110 per cent.


GlaxoSmithKline to sell Lucozade in China

Drug multinational GlaxoSmithKline said it would sell, Lucozade, the energy drink, in the Chinese supermarkets, a move signifying drug-maker's effort to push itself into the emerging markets of the world.

GlaxoSmithKline has penned a deal with President Trading to distribute it through out China.

Lucozade was first invented by a Newcastle chemist in 1927 to provide ailing children a glucose boost.

Lucozade, which is mainly sold in Britain, Hong Kong and Ireland, generates around 400 million pounds in sales annually.


Abcam posts £16.3m pre-tax profits; lifts dividend

Antibody supplier Abcam has shunned the economic slump by pocketing pre-tax profits worth £16.3 million for the year to June as compared to £8 million in the previous year.

Catalogue-based Abcam said that its revenues jumped by 55.2 per cent to settle at £56.8 millionb against £36.6 million in 2008.

Firm’s product-range grew 19 per cent, from 44,000 antibodies in 2008 to around 52,400 antibodies.


Supply shortage of certain medicine causing “extreme distress” in patients

According to a recent survey published on the website of Chemist & Druggist, as many as 50 out-of-stock medicines have become a reason for "extreme distress" for patients, who are facing inconvenience due to the shortages in supply.

In the nearly 150 community pharmacies surveyed, almost one-third reported that patients have been troubled by the shortfall of certain medicines, including those for breast cancer, blood clots, and antidepressants. Nearly 90 of respondents stated they were "very concerned" about the short supplies.



Subscribe to RSS - Pharmaceutical Sector